文献检索

查找使用阿拉丁产品的科研文献

检索与阿拉丁产品相关的同行评审论文、DOI、PubMed 编号、期刊、作者、CAS 号及研究领域。

科研影响力快照

与阿拉丁产品相关的已发表科研成果

在搜索之前,这些指标可帮助访客快速了解产品关联科研的规模与质量。

346,364+ SCI 论文 与阿拉丁产品引用相关
2,295,288.15 总影响因子 匹配文献记录中影响因子的总和
81.20 最高期刊影响因子 匹配期刊中的最高 IF
6.63 平均期刊影响因子 匹配文献的平均 IF

参考指标 指标基于阿拉丁文献引用数据库及期刊影响因子记录。文献关联仅供科研参考,请以原始文献为准。

热门产品

视图 列表 网格

2 项

设置提升方向
125I粒子
MACROMOLECULAR RESEARCH · 2021 ·Vol. 29 ·期 11 ·818-824 · IF 2.227

Two Luminescent Cd(II) Coordination Polymers: Enhancement Activity on Pancreatic Cancer Combined with Biliary Stent Placement and 125I Particles

Jia Jie-Peng,Shao Quan,Wang Ying-Kai,Qian Bo,Zhang Wen,Hu Tao,Zhang Ji-Jun

With the reaction between bib ligands, 5-substituted isophthalic acid and Cd(II) ions, we produced two coordination polymers in success, that is, [Cd(5-meo-ip) (bib) 0.5 ] n (2) and [Cd(5-me-ip)(bib)(H 2 O)] n ·n(H 2 O] (1) (bib is 1,4-bis(imidazoly)butane, 5-meo-H 2 ip is 5-methoxyisophthalic acid, and 5-me-H 2 ip is 5-methylisophthalic acid). The luminescent performances and thermal stability of the two compounds were also explored. Their anti-pancreatic cancer activity combined with biliary stent placement and 125I particles was evaluated and the specific mechanism was explored as well. Firstly, after the model construction and compound treatment, the weight and volume of the tumor tissue was measured. Next, the apoptosis level of the cancer cells were evaluated with Annexin V-FITC/PI apoptosis assay.

CAS / MDL: 46331-50-4
研究领域: 肿瘤学 · 材料科学 · 放射治疗学
✓ 已验证 产品关联 DOI 高影响因子
查看原文 查看 PubMed
Bioengineering & Translational Medicine · 2025 · IF 5.7

A novel brachytherapy and chemotherapy integrated ureteral stent: In vitro and in vivo study

Xiaotian Yang,Xueliang Zhou,Zhanyun Zhou,Yipu Li,Chengzhi Zhang,Yingqi Liu,Xiaohan Ma,Yanan Li,Yebin Wang,Dechao Jiao

Ureteral carcinoma remains a major clinical challenge and requires effective localized treatment. Here, we report a novel 125 I seed brachytherapy (ISB) and doxorubicin (DOX) chemotherapy integrated ureteral stent (IUS), which enables simultaneous urinary drainage and chemoradiotherapy. This study was divided into three parts. First, ISB and DOX significantly reduced T24 cell viability and inhibited migration and invasion in an in vivo study ( p < 0.01). Second, a T24 xenograft mouse model demonstrated that the (DOX + ISB) group exhibited greater tumor suppression than the DOX ( p = 0.08) and ISB ( p = 0.02) groups, with decreased Ki-67 and Bcl-2 expression and increased apoptosis (all p < 0.01) in an in vitro study. Third, the IUS was successfully implanted in normal beagle dogs ( n = 30) without surgical complications. The ureteral diameter increased with increasing cumulative brachytherapy and sustained DOX release ( p < 0.05). Histological analysis revealed progressive tissue damage and fibrosis, with increased expression of α-SMA, Caspase-3, and Collagen-1 in the 0.8 mCi + 20 mg DOX group ( p < 0.05), whereas PCNA expression was highest in the Control group (0 mCi + 0 mg DOX). In conclusion, the newly designed IUS is safe and technically feasible in animals; clinical studies will be required to evaluate its use in humans.

CAS / MDL: 67-68-5
✓ 已验证 产品关联 DOI PubMed 高影响因子
查看原文 查看 PubMed
已复制

文献关联基于可获得的产品、CAS、DOI 及引用记录。收录不代表作者或出版方对阿拉丁产品的背书,请以原始文献为准。